IIF vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating significant financial instability. While the fund trades at a discount to book value (P/B 0.79), this is offset by a highly unsustainable dividend payout ratio of 183.62% and negative operating margins of -108.90%. Severe liquidity concerns are evident in the current ratio of 0.04, and bearish insider sentiment is confirmed by $1.93M in net selling. Overall, the fund exhibits characteristics of a dividend trap with deteriorating fundamentals.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
IIF vs JPM: Head-to-Head Comparison
This page compares Morgan Stanley India Investment Fund, Inc. (IIF) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.